Stockscreener 앱 받기
12.30
2.15%
-0.27
전일 마감가:
$12.57
열려 있는:
$12.56
하루 거래량:
1,762
Relative Volume:
0.51
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.23%
1개월 성능:
+1.49%
6개월 성능:
-18.27%
1년 성능:
-22.40%
1일 변동 폭
$12.30
$12.59
1주일 범위
$12.30
$13.00
52주 변동 폭
$11.38
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
CNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
12.30 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
295.92 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
599.94 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
602.87 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
239.61 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
526.08 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf 주식(CNCR)의 최신 뉴스
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail
Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
7 Best-Performing Biotech ETFs for February 2025 - NerdWallet
When (CNCR) Moves Investors should Listen - Stock Traders Daily
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
Reston Hospital Center adds inpatient unit to expand its range of oncology services - Yahoo Finance
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Looking for Gold Exposure in 2025? 3 ETFs to Consider - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
(CNCR) Investment Analysis - Stock Traders Daily
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer (LPTX) - Seeking Alpha
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Texas Instruments (TXN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Science & Technology | TBR News Media | Page 2 - TBR News Media
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR - GlobeNewswire Inc.
(CNCR) Trading Report - Stock Traders Daily
Enbridge Inc (ENB-N) QuotePress Release - The Globe and Mail
Cold Spring Harbor Laboratory - TBR News Media
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields (NVCR) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
Daniel Dunaief - TBR News Media
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Trackinsight ETF data from 11th to 15th November, 2024 - ETF Express
The Best Biotech Stocks to Buy - Morningstar
Charted: Cancer Survival Rates Over Time - Visual Capitalist
Range Cancer Therapeutics - TBR News Media
How this award-winning TV host is setting the stage to help protect her health - TBR News Media
Investment fund pledges revenues in cancer research partnership with CSHL - TBR News Media
(CNCR) Trading Signals - Stock Traders Daily
At a Glance: Nov. 6 - Crain's New York Business
The 5 Best Biotech ETFs of 2024 - TradingView
Seagen’s Ex-CEO Starts Company to Develop Drug Tackling Wide Range of Cancers - BNN Bloomberg
Canadian Alternatives to Popular U.S. ETFs: How to Invest in SPY, QQQ, and More - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology - Yahoo Finance
(CNCR) Investment Report - Stock Traders Daily
How are ADC drug partnerships changing China’s biotech landscape? - Invesco
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market - Seeking Alpha
Range Cancer Therapeutics Etf (CNCR) 재무 분석
Range Cancer Therapeutics Etf (CNCR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):